0NZU Stock Overview A biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. More details
Rewards Risk Analysis No risks detected for 0NZU from our risk checks.
See All Risk Checks Capture your thoughts, links and company narrative
Zealand Pharma A/S Competitors Price History & Performance
Summary of share price highs, lows and changes for Zealand Pharma Historical stock prices Current Share Price DKK 717.03 52 Week High DKK 969.00 52 Week Low DKK 529.00 Beta 0.54 1 Month Change -3.01% 3 Month Change -1.30% 1 Year Change 50.04% 3 Year Change 612.63% 5 Year Change 192.67% Change since IPO 970.20%
Recent News & Updates
Zealand Pharma A/S, Annual General Meeting, Mar 27, 2025 Feb 21
Forecast breakeven date pushed back to 2026 Feb 21
Full year 2024 earnings released: kr.16.24 loss per share (vs kr.12.44 loss in FY 2023) Feb 21
Now 20% overvalued after recent price rise Feb 18
New minor risk - Share price stability Dec 25
Zealand Pharma A/S Announces U.S. Food and Drug Administration Issues Complete Response Letter for the New Drug Application for the Treatment of Short Bowel Syndrome Dec 20 See more updates
Zealand Pharma A/S, Annual General Meeting, Mar 27, 2025 Feb 21
Forecast breakeven date pushed back to 2026 Feb 21
Full year 2024 earnings released: kr.16.24 loss per share (vs kr.12.44 loss in FY 2023) Feb 21
Now 20% overvalued after recent price rise Feb 18
New minor risk - Share price stability Dec 25
Zealand Pharma A/S Announces U.S. Food and Drug Administration Issues Complete Response Letter for the New Drug Application for the Treatment of Short Bowel Syndrome Dec 20
Employee Representative Director recently sold kr.1.3m worth of stock Nov 13
Forecast to breakeven in 2025 Nov 11
Forecast to breakeven in 2025 Nov 08
Third quarter 2024 earnings released: kr.3.77 loss per share (vs kr.1.27 profit in 3Q 2023) Nov 08 Zealand Pharma A/S to Report Q1, 2025 Results on May 08, 2025
Zealand Pharma Provides U.S. Regulatory Update on Dasiglucagon in Congenital Hyperinsulinism Oct 09
Insufficient new directors Oct 01
President & CEO recently sold kr.31m worth of stock Sep 03
Second quarter 2024 earnings released: kr.4.67 loss per share (vs kr.5.50 loss in 2Q 2023) Aug 16
Zealand Pharma A/S Appoints Eric Cox as Chief Commercial Officer, Effective August 5, 2024 Jul 30 Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 6.257 billion.
Zealand Pharma A/S Announces Positive Topline Results from the Phase 1B 16-Week Multiple Ascending Dose Clinical Trial with Long-Acting Amylin Analog Petrelintide Jun 21
Zealand Pharma A/S Announces Boehringer Ingelheim Will Present Positive Results from Phase 2 Trial with Survivalodutide in MASH at EASL Jun 08
Zealand Pharma Announces Topline Results from the Mechanistic Investigator-Led Dream Trial with Low Doses of GLP-1/GLP-2 Receptor Dual Agonist Dapiglutide May 25
Zealand Pharma A/S Approves Appointments to the Board Mar 21
Zealand Pharma A/S Announces Board Changes Mar 14
Zealand Pharma A/S Announces Boehringer Ingelheim Survodutide Phase 2 Trial Shows 83% of Adults Treated a Statistically Significant Improvement of Metabolic Dysfunction-Associated Steatohepatitis Feb 27
Zealand Pharma A/S, Annual General Meeting, Mar 20, 2024 Jan 13 Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 1.45362 billion. Jan 12
Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 1.45362 billion. Jan 09
Zealand Pharma A/S Appoints Enrique Conterno and Elaine Sullivan as Board Observers Nov 30 Zealand Pharma A/S to Report Q1, 2024 Results on May 16, 2024
Boehringer Ingelheim and Zealand Pharma A/S Announces Initiation of Three Phase III Trials Oct 06
Zealand Pharma A/S Announces Designation of Priority Review by the US FDA for Dasiglucagon in Congital Hyperinsulinism Aug 30
Zealand Pharma A/S Announces Positive Results from Part 1 of Multiple Ascending Dosing Trial with Amylin Analog ZP8396 Jul 04
Zealand Pharma Submits Marketing Authorization Application for Dasiglucagon for Treatment of Severe Hypoglycemia in Diabetes to the European Medicines Agency Jun 27
Boehringer Ingelheim and Zealand Pharma A/S Announces Phase II Trial Showed 14.9% Weight Loss in People Living with Obesity or Unveil May 11 Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 786.05 million. Oct 06
Zealand Pharma A/S Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (Ease 1)
Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism At the 60Th Annual Espe Meeting Sep 19
Zealand Pharma A/S Announces Chief Financial Officer Changes Aug 25
Zealand Pharma A/S Revises Revenue Guidance for the Full Year of 2022 Aug 12 Zealand Pharma Announces Voluntary Delisting of American Depositary Shares from the Nasdaq Global Select Market Aug 09
Zealand Pharma A/S Presents Data from Phase 1 Trial of Dapiglutide and to Move into Phase 2 Trial for Obesity Jun 07
Zealand Pharma Announces Appoints David M. Kendall, as Chief Medical Officer Jun 02
Insufficient new directors Jun 01
Zealand Pharma A/S Announces Positive Top-Line Results from Its Second Phase 3 Clinical Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism May 20
Zealand Pharma A/S (CPSE:ZEAL) entered into an agreement to acquire V-Go® Insulin Delivery Device from Zealand Pharma for $10 million. May 18
First quarter 2022 earnings released: kr.4.19 loss per share (vs kr.5.77 loss in 1Q 2021) May 16
Insufficient new directors May 02
Zealand Pharma Announces CEO Changes Mar 31
Full year 2021 earnings: Revenues in line with analyst expectations Mar 12
Zealand Pharma A/S Announces Completion of Patient Enrollment in the Second Phase 3-Trial, 17103 in Children with Congenital Hyperinsulinism Feb 15
Zealand Pharma Completes Enrollment in Ease-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome Jan 22
Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome Dec 17
Zealand Pharma A/S announced that it expects to receive $200 million in funding from Oberland Capital Management LLC Dec 16
Zealand Pharma Announces Successful Outcome of Phase 1B Clinical Trial with GLP1-GLP2 Dual Receptor Agonist, Dapiglutide Nov 24
Third quarter 2021 earnings released: kr.4.61 loss per share (vs kr.5.76 loss in 3Q 2020) Nov 12
Zealand Pharma A/S Presents Data At 2021 ESPEN Virtual Congress Demonstrating Dose-Dependent Effects of Glepaglutide in Both Small and Large Intestines of Animal Models –in Contrast to Short-Acting GLP-2 Sep 10
Employee Elected Director Gertrud Rasmussen has left the company Sep 03
Employee Elected Director Gertrud Rasmussen has left the company Sep 03
Zealand Pharma Announces First Patient Dosed in EASE-SBS 4 Phase 3b Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome Aug 20
Protagonist Therapeutics, Inc Announces Resolution of Contract Dispute with Zealand Pharma Aug 12
Zealand Pharma Announces U.S. Commercial Availability of Zegalogue (Dasiglucagon) Injection Jun 25
Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH Jun 03
Zealand Pharma A/S Receives First FDA Approval and Prepares for Launch of Zegalogue® (Dasiglucagon) Injection May 14
First quarter 2021 earnings released: kr.5.78 loss per share (vs kr.4.98 loss in 1Q 2020) May 13
Zealand Pharma A/S Reaffirms Earnings Guidance for the Full Year of 2021 May 13
Zealand Pharma A/S Announces Publication of Phase 3 Trial Evaluating Efficacy and Safety of Dasiglucagon for Treatment of Severe Hypoglycemia in Adult Patients with Diabetes May 04
Full year 2020 earnings released: kr.22.07 loss per share (vs kr.16.91 loss in FY 2019) Mar 14
Revenue misses expectations Mar 14
New 90-day low: kr.192 Feb 23
New 90-day low: kr.202 Jan 29
Zealand Pharma A/S Announces Data from the First Phase 3-Trial with Dasiglucagon in Congenital Hyperinsulinism (Chi) Dec 17 Zealand Pharma A/S to Report Q3, 2021 Results on Nov 11, 2021
Third quarter 2020 earnings released: kr.5.76 loss per share Nov 13
Revenue misses expectations Nov 13 Zealand Pharma Continues to Advance Clinical Programs and Commercial Launch Capabilities
New 90-day low: kr.211 Oct 29
New 90-day high: kr.245 Oct 01
Zealand Pharma A/S (CPSE:ZEAL) completed the acquisition of substantially all assets of Valeritas Holdings, Inc. Jul 31 Shareholder Returns 0NZU GB Biotechs GB Market 7D -4.7% -4.9% -0.9% 1Y 50.0% -16.3% 9.8%
See full shareholder returns
Return vs Industry: 0NZU exceeded the UK Biotechs industry which returned -16.3% over the past year.
Return vs Market: 0NZU exceeded the UK Market which returned 9.8% over the past year.
Price Volatility Is 0NZU's price volatile compared to industry and market? 0NZU volatility 0NZU Average Weekly Movement 6.4% Biotechs Industry Average Movement 8.0% Market Average Movement 4.6% 10% most volatile stocks in GB Market 10.6% 10% least volatile stocks in GB Market 2.5%
Stable Share Price: 0NZU has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0NZU's weekly volatility (6%) has been stable over the past year.
About the Company Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.
Show more Zealand Pharma A/S Fundamentals Summary How do Zealand Pharma's earnings and revenue compare to its market cap? 0NZU fundamental statistics Market cap DKK 50.44b Earnings (TTM ) -DKK 1.08b Revenue (TTM ) DKK 62.69m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0NZU income statement (TTM ) Revenue DKK 62.69m Cost of Revenue DKK 7.87m Gross Profit DKK 54.82m Other Expenses DKK 1.13b Earnings -DKK 1.08b
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 08, 2025
Earnings per share (EPS) -15.27 Gross Margin 87.44% Net Profit Margin -1,720.87% Debt/Equity Ratio 3.3%
How did 0NZU perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/22 14:01 End of Day Share Price 2025/02/21 00:00 Earnings 2024/12/31 Annual Earnings 2024/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Zealand Pharma A/S is covered by 24 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Laura Hindley Berenberg Kerry Holford Berenberg Charlie Haywood BofA Global Research
Show 21 more analysts 
